FSFedor Evgenievich Shadrichev

Fedor Evgenievich Shadrichev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fedor Evgenievich Shadrichev has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cost analysis of aflibercept 8 mg versus other anti-VEGF agents

    by F.E. Shadrichev, Yu.V. Strunina

    Purpose. This study aimed to assess the economic impact of aflibercept 8 mg (114.3 mg/ml, 0.263 ml; hereinafter aflibercept 8 mg) compared with alternative anti-VEGF agents in adult patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) over a 2-year treatment period. Material and methods. The study compared different anti-VEGF therapies (aflibercept 8 mg; aflibercept 2 mg — 40 mg/ml, 0.278 ml; brolucizumab 6 mg — 120 mg/ml, 0.23 ml; ranibizumab 0.5 mg — 10 mg/ml, 0.23 ml) from the perspective of the healthcare system of the Russian Federation over a 2-year horizon. The number of intravitreal injections was determined based on an indirect comparative analysis; the number of administrations was reconstructed using an anchor value for aflibercept 8 mg and published differences in injection frequencies. Costs were calculated using the weighted average procurement price per package. The burden on the compulsory health insurance (CHI) system was estimated based on the average cost per insurance case (Diagnosis-Related Group, DRG, for “Intravitreal drug administration”) of 47 459.63 RUB. Results. The costs over 2 years were lower with aflibercept 8 mg, resulting in savings of 99 713—140 434 RUB per patient with nAMD and 98 305—173 196 RUB with DME, depending on the comparator drug. When assessing the burden on the CHI system, savings amounted to 142 378—489 783 RUB per patient with nAMD and 119 598—541 039 RUB per patient with DME. Conclusion. The use of aflibercept 8 mg in nAMD and DME reduces both direct treatment costs and expenditures of the CHI system in the first and second years of therapy, as well as cumulatively over 2 years. The results remain robust under price reductions and support the economic feasibility of the use of aflibercept 8 mg.

  • Results of the anonymous independent Russianlanguage survey of retinologists “SETCHAtochkaRU — 2025”

    by E. V. Bobykin, R. R. Fayzrakhmanov, S. Yu. Golubev, T. I. Dibaev, O. V. Zaytseva, V. N. Kazaikin, E. A. Larina, D. S. Maltsev, N. V. Neroeva, P. A. Nechiporenko, et al.

    Retinology is undoubtedly the avant-garde of modern ophthalmology and develops rapidly. The development and implementation of newest scientific and technological advances in clinical practice contribute to the continuous improvement of diagnostics and various treatments for posterior segment pathologies. At the same time, there are certain national and regional medicine development aspects, as well as controversial issues that can be successfully explored through sociological research, particularly expert surveys. In 2024, we organized and conducted the first independent Russian survey of retinologists, “SETCHAtochkaRU”, aimed at collecting and analyzing data on current practices, opinions, equipment, and challenges in the diagnosis and treatment of vitreoretinal pathology in Russia. The project yielded unique insights and was well received by both respondents and the scientific community. For this reason, we decided to repeat the survey a year later and attempt to make it a regular event, which will allow us to discuss the most modern aspects of retinology and evaluate its development trends. The “SETCHAtochkaRU — 2025” survey involved 430 specialists representing all regions of the Russian Federation, as well as Belarus, Germany, Georgia, Kazakhstan, Kyrgyzstan, Croatia, and Uzbekistan. The updated list of questions included such topical and relevant issues as the perspectives for the artificial intelligence use, antiangiogenic therapy trends (new drugs, biosimilars, regimens, and drug switching strategies), various practical aspects of drug use, laser, and surgical treatment for vitreoretinal pathology, the results of the federal project “Fight Against Diabetes”, and many others. Analysis of the survey results revealed a number of positive trends in the development of Russian ophthalmology. In our opinion, the “SETCHAtochkaRU” project has the potential to develop and improve as an annual monitoring study, generating original evidence base tailored to national specifics.

  • Open Access

    Results of the first Russian survey of retinologists “SETCHAtochkaRU”

    by E. V. Bobykin, R. R. Fayzrakhmanov, S. Yu. Golubev, T. I. Dibaev, O. V. Zaytseva, V. N. Kazaikin, E. A. Larina, D. S. Maltsev, N. V. Neroeva, P. A. Nechiporenko, et al.

    Disorders of the posterior segment of the eye are traditionally one of the most important medical and social problem. The rapid development in the ophthalmology field in the 20th and 21st centuries has led to a significant improvement in the knowledge on the physiology and pathology of the light-perceiving eye structures, revolutionary achievements in the diagnosis and treatment of a wide range of retinal diseases, optic nerve, choroid and vitreous body pathology. The need for highly qualified physicians with a modern understanding of this problem led to the emergence of an ophthalmological specialization called “retinology”. Modern retinology includes various areas of diagnostics (including visualization of eye structures, electrophysiological and genetic methods), as well as drug, laser and microsurgical treatment and rehabilitation of the patients. In the rapidly developing medicine, sociological research is extremely important, allowing health care organizers to assess existing trends and make decisions determining the development direction in the field, and specialists to exchange opinions and analyze their professional activities. Retinology is no exception. Surveys of professional organizations of retinologists that have great scientific and practical significance are successfully conducted abroad, the most famous of which are the EURETINA Clinical Trends Survey and the ASRS Preferences and Trends (PAT) Survey. In Russia, such surveys have not been conducted to date. At the same time, the opportunity to learn the opinions of Russian specialists, as well as to compare domestic and foreign data is of undoubted interest. In 2024, we organized and conducted the first independent Russian survey of retinologists “SETCHAtochkaRU”, in which 585 ophthalmologists from all federal districts of the Russian Federation took part, as well as our colleagues from Belarus, Kazakhstan, Kyrgyzstan, Latvia, Lebanon, Tajikistan, Turkmenistan, Turkey and Uzbekistan. The main results of the survey are presented in this publication.


  • Open Access

    Practical application of semaglutide: From evidence-based research to expert decisions

    by V. V. Salukhov, G. R. Galstyan, Iu. Sh. Khalimov, I. G. Bakulin, D. V. Cherkashin, F. E. Shadrichev, N. A. Sukhotskaia, Ю. Ш. Халимов

    The rapid progress in the development of highly effective weekly incretin-based medications offers increasingly broad opportunities for comprehensive correction of cardiometabolic disorders in patients with type 2 diabetes and/or obesity. This article aims to summarize existing research that confirms the efficacy and safety of one of the most prescribed medications from the class of glucagon-like peptide-1 receptor agonists – weekly semaglutide. In addition to presenting the main results of randomized clinical trials involving semaglutide, special emphasis is placed on experimental and clinical studies related to the drug’s effectiveness in real-world conditions and during specific life periods for patients with type 2 diabetes and/or obesity, such as surgical and endoscopic interventions, bariatric surgery, intermittent fasting, and religious dietary restrictions. Based on this evidence base and their own clinical experience, the interdisciplinary author team proposes practical approaches to adjusting hypoglycemic therapy in patients with type 2 diabetes when combined with semaglutide and switching to other therapies. Practical recommendations for the use of the drug in patients with obesity during the active weight loss phase and the weight maintenance phase are also formulated. Key considerations supporting long-term obesity treatment are presented; however, trial de-escalation therapy schemes are also provided for patients who have successfully modified their lifestyle while achieving target weight outcomes. The reasons and mechanisms behind the most common adverse events associated with semaglutide use, which represent a potential barrier to its utilization, are separately discussed. The most effective measures for their prevention and correction are outlined, which will enable the realization of the therapeutic potential of weekly semaglutide and thus improve patient outcomes in the long-term management of obesity and type 2 diabetes.


  • Open Access

    ИЗМЕНЕНИЕ КАПИЛЛЯРНОЙ ПЕРФУЗИИ В МАКУЛЯРНОЙ ЗОНЕ У ПАЦИЕНТОВ С ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИЕЙ

    by Тульцева С.н., Огнева Т.р, Патрина Е.а., Шадричев Ф.E.

    Relevance. The main causes of progressive and often bilateral vision loss in patients with diabetes are diabetic macular edema and ischemic maculopathy (IM). The prevalence and severity of IM in patients with preproliferative stage diabetic retinopathy (DR) is unknown. Purpose of the study. To investigate the prevalence and severity of IM using optical coherence tomography with function of angiography (OCTA) marker assessment in compensated diabetic patients with preproliferative stage DR. Materials and methods. 26 patients (58 [32; 78] years) (44 eyes) were included in the study: 14 men (24 eyes) and 12 women (20 eyes). Each patient had standard ophthalmological examination, optical coherence tomography in angiography (OCTA) mode. The following were used as markers of ischemic maculopathy: density of capillary perfusion and vessels in the superficial capillary plexus in the macular zone (MZ), length of the circumference of the avascular zone, bestcorrected visual acuity (BCVA), retinal thickness in the MZ. All patients were divided into comparison groups according to the IM grade (from 0 to 8) (IM classification based on FAG data but corrected for OCTA, Early Treatment of Diabetic Retinopathy Study protocol. Grading of diabetic macular ischemia according to ETDRS Report No. 11). Results and conclusion. In patients with the preproliferative stage of DR, the mean capillary perfusion density in the MZ was 17.4 [3.8; 29.3] %, vessel density in the MZ of the superficial capillary plexus was 9.6 [2.5; 17.5] %, avascular zone circumference length was 0.25 [0.05; 0.69] μm, BVCA was 0.7 [0.1; 1.0], and retinal thickness in the MZ was 265 [203; 750] μm. The glycated hemoglobin level was 8.1 [6.2;13.2] mmol/l. Level IM - 0 was not detected in the presented sample (group 1, 0 eyes), level IM - 1 was detected in 22 patients (group 2, 36 eyes), and 4 patients (group 3, 8 eyes) had level IM - 2. A statistically significant difference between groups 2 and 3 was found between capillary perfusion density scores (18.4 [5.8; 29.3] % against 6.4 [2.5; 8.7]) % (p<0.001), vessel density in the superficial capillary plexus (10 [2.6; 17.5] % against 12.7 [3.8; 16.7] %) (p<0.01), and avascular circumference length (0.22 [0.05; 0.3] against 0.4 [0.32; 0.7]) μm (p<0.001). Decreased capillary perfusion, decreased vascular density, and increased circumferential length of the avascular zone were present in all patients with preproliferative DR. The presence and severity of IM did not depend on the type of diabetes mellitus and the presence of diabetic macular edema. In the patient sample studied, the degree of IM correlated with vessel density and perfusion in the macular zone. At level IM - 1 and IM - 2, no correlation was found between MCOS and the circumference length of the avascular zone. At level IM - 1 and IM - 2, there was no correlation between BVCA and the length of the avascular zone.

  • Open Access

    Ischemic maculopathy at the preproliferative stage of diabetic retinopathy: epidemiology, clinical picture and diagnosis

    by Tatyana R. Ogneva, Svetlana N. Tultseva, Fedor E. Shadrichev, Ekaterina A. Patrina

    BACKGROUND: One of the leading causes of central vision loss in patients with diabetic retinopathy is ischemic maculopathy, the incidence of which in diabetic retinopathy varies depending on the stage of the disease from 20 to 77% according to fluorescein angiography results. More accurate diagnosis of ischemic maculopathy is possible using the technique of optical coherence tomography angiography (OCTA). AIM: To study the prevalence and severity of ischemic maculopathy in patients with diabetes mellitus type 1 and 2 with preproliferative stage of diabetic retinopathy using OCTA. MATERIALS AND METHODS: 43 patients (72 eyes) of diabetic retinopathy levels 47 and 53, according to ETDRS criterions, were included in the study. The exclusion criterion was the presence of diabetic macular edema with involvement of the center of the macula. Patients were divided into 3 groups according to the ETDRS classification of ischemic maculopathy grade. Each of them was subject to standard ophthalmologic examination, OCT with determination with determination of central retinal thickness in macula zone and OCTA to evaluate the status of the foveolar avascular zone. RESULTS: Ischemic maculopathy level 1 was detected in 23 patients — group 1 (33 eyes), level 2 was detected in 23 patients (27 eyes) — group 2, and level 3 — in 8 patients (12 eyes) — group 3. A statistically significant difference using “IBM SPSS Statistics” version 27 was found between the foveolar avascular zone area scores of groups 1 and 2 — 0.18 mm2 versus 0.32 mm2 (p 0.001) and between groups 1 and 3 — 0.18 mm2 versus 0.98 mm2 (p 0.001), and between groups 2 and 3 — 0.32 mm2 versus 0.98 mm2 (p 0.008). In group 3, negative correlations were found between best-corrected visual acuity and foveolar avascular zone circumference length (r = –0.906, p = 0.02), foveolar avascular zone (r = –0.748, p = 0.033) and circularity index (r = –0.569, p = 0.141), while no such statistically significant difference was found in the other groups. CONCLUSIONS: In patients with diabetic retinopathy levels 47 and 53, ischemic maculopathy is revealed in 100% of cases. In 83.4% of cases, level 2 of the ischemic maculopathy is detected, and in 16.6% — level 3. Ischemic maculopathy of levels 1 and 2 has no significant effect on best-corrected visual acuity. Level 3 is clinically significant, as the change of parameters characterizing foveolar avascular zone, and first of all the increase of foveolar avascular zone circumference length above 500 µm, is associated with a decrease in best-corrected visual acuity.


  • Open Access

    Interdisciplinary approach to the management of diabetic retinopathy: The role of ophthalmologist and endocrinologist

    by Tatiana Demidova, Fedor Shadrichev, Н. Н. Григорьева, Valentina Fisher, Fatima Ushanova, Margarita Nadybina, Regional Endocrinological Center “City Consultative And Diagnostic Center No. 1”, Nyurguyana Grigorieva

    Diabetic retinopathy (DR) and diabetic macular edema (DME) are common chronic complications of diabetes mellitus, the fight against which is an urgent problem of modern healthcare. DR is the fifth most common cause of blindness worldwide and the main cause of vision loss in patients with diabetes. An interdisciplinary approach plays a key role in the effective management of DR, in which the role of the endocrinologist is to achieve optimal indicators of glycemic control as the main pathogenetic factor, and regular referral to screening of patients from risk groups. In turn, ophthalmologists are faced with the task of directly diagnosing changes in the fundus and treating eye diseases at various stages. Modern ideas about the mechanisms of development of DR and the role of VEGF allow us to identify several main areas of therapy. Thus, the main method of treating DR is laser retinal coagulation (LRC), and the most effective method of treating DME is considered to be a combination of LRC and intravitreal administration of angiogenesis inhibitors. Currently, intravitreal administration of agents that prevent the neoangiogenesis is the first-line treatment for DME involving the center of the macula. This review provides information on the pathogenesis, modern classification and current approaches to the management of patients with DR in the framework of the interaction of an ophthalmologist and an endocrinologist.

  • Open Access

    COVID-19 as a new risk factor for the development of acute vascular diseases of the optic nerve and retina

    by Vadim A. Turgel, Vladimir A. Antonov, Svetlana N. Tultseva, Fedor E. Shadrichev, Niurguyana N. Grigorieva, Григорьева Нургуяна Николаевна

    The new coronavirus disease (COVID-19) is a viral respiratory infection accompanied by systemic endotheliitis. COVID-19 patients usually encounter changes related to hypercoagulability, hypofibrinolysis, and increased intravascular platelet aggregation. There is also a vascular wall thromboresistance decrease and impaired vasomotor function, which significantly increase the risk of thromboembolic complications. Currently, pathogenic aspects of the relationship between COVID-19 and vascular and inflammatory conditions of the optic nerve and retina are actively investigated. One of the triggers of impaired blood flow in ocular vessels may be a perfusion pressure decrease, observed in the acute period of the infectious process. This is related to both COVID-19 clinical course features and to resuscitation specificity as well. Secondary autoimmune inflammation is being considered as a mechanism of damage to the vascular wall in the post-infectious period. In this publication, possible pathogenic links of these diseases are considered for the first time in a specific context of the example of ischemic optic neuropathy associated with coronavirus infection.


  • Open Access

    An information leaflet for patients receiving treatment by intravitreal drug injections. Recommendations of the Expert Council on retinal and optic nerve diseases of the Association of Ophthalmologists, an All-Russian public organization

    by V. V. Neroev, S. A. Korotkikh, E. V. Bobykin, O. V. Zaytseva, A. B. Lisochkina, A. F. Brovkina, M. V. Budzinskaya, M. V. Gatsu, N. N. Grigoryeva, A. S. Izmaylov, et al.

    The widespread introduction of intravitreal drug injections into clinical practice has highlighted a number of issues to be solved, including the risk of serious complications, the treatment burden on patients and the patient’s insufficient adherence to treatment, as well as a significant effect on the healthcare cost and effort. One of the ways to resolve the issues is to increase the patients’ awareness concerning the therapy they are about to receive, which contributes to the patients’ understanding of the details of treatment and enables them to make correct decisions. The best option of presenting such information to the patient is to provide them with a written document. The Expert Council on Retinal and Optic Nerve Diseases of the All-Russian Association of Ophthalmologists has developed, approved and tested an information brochure for patients who receive intravitreal injections. It offers brief information on what the procedure is, contraindications, details of preparation, and symptoms, both common ones and those requiring emergency assistance. The paper outlines the results of the study and presents a layout of an information leaflet for patients recommended for use in the Russian Federation.


  • Prevention of blindness in diabetes mellitus. From retinal laser coagulation to pharmacology

    by F.E. Shadrichev ( Shadrichev, T. Yu. Demidova () Demidova, N.N. Grigorieva ( Grigorieva, A.A. Kozhevnikov () Kozhevnikov, St. Petersburg Territorial Diabetes Center 2) City Consultative And Diagnostic Center № 1